| Literature DB >> 34201328 |
Reham AlJasser1, Sundus Bukhary2, Mohammed AlSarhan1, Dalal Alotaibi1, Saleh AlOraini1, Syed Rashid Habib3.
Abstract
The aim of this in-vivo study was to evaluate/compare the clinical periodontal parameters in patients with true combined endo-perio lesions (EPL), treated with gutta-percha (GP) and mineral trioxide (MTA) as an obturation material alone and with addition of bone grafting in such lesions. 120 Saudi patients (mean age = 41yrs) diagnosed with true combined EPL participated in this study. Group I (control group, n = 30) was treated with conventional endodontic treatment using GP for obturation. Group II (n = 30) was treated with conventional endodontic treatment using MTA for obturation. Group III (n = 30) was treated with conventional endodontic treatment using GP for obturation + grafting procedure to fill the bony defect. Group IV (n = 30) was treated with conventional endodontic treatment using MTA for obturation + grafting procedure to fill the bony defect. Clinical parameters (Pocket depth (PD); Clinical attachment loss (CAL); keratinized tissue width (KTW); gingival phenotype (G.Ph.) and Cone Beam Computed Tomography Periapical Index (CBCTPAI)) were recorded and compared at baseline, 3, 6, 12 months' interval. For the groups III and IV, CBCTPAI showed significant difference (p < 0.0001) with the other groups at 6 months and 1-year interval. The group with MTA + bone graft showed 76% and 90% patients with 0 score at 6 months and 1-year follow-up, respectively. Comparison of mean values of PD among study groups at 3 months, 6 months and 1 year showed significant difference at 3 months, whereas the mean PD values of subjects in GP + bone graft showed significantly higher PD values than other 3 groups (p = 0.025). Use of GP and MTA for root canal obturation along with periodontal therapy and bone augmentation helps in resolving complex endo-perio lesions. Bone grafting in addition to obturation with MTA was found to be the best treatment strategy in management of EPL cases and is recommended for clinicians who are treating EPL patients.Entities:
Keywords: MTA; bone grafting; endo-perio lesions; endodontic therapy; mineral trioxide; periodontal therapy
Mesh:
Substances:
Year: 2021 PMID: 34201328 PMCID: PMC8227857 DOI: 10.3390/ijerph18126220
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Details of the tested groups and materials used in the research study.
| S. No. | Group | Treatment | Obturation/Graft Material | Trade Name | Lot Number |
|---|---|---|---|---|---|
| 1. | Group-I | Conventional non-surgical RCT performing standard methodology | Gutta Percha | Obtura Gutta Percha Bar PK/100 Bar | FD-MT057 |
| 2. | Group-II | Conventional non-surgical RCT performing standard methodology | Mineral trioxide aggregate | ProRoot MTA, White, 10 × 0.5 g | MP-A040500000400 |
| 3. | Group-III | Conventional non-surgical RCT performing standard methodology | Gutta Percha | Obtura Gutta Percha Bar PK/100 Bar | FD-MT057 |
| Bone graft | AlloOss. Natural Blend Cortico/Cancellous Particulate, 500–1000 mic. | SKU: 01-108-201 | |||
| 4. | Group-IV | Conventional non-surgical RCT performing standard methodology | Mineral trioxide aggregate | ProRoot MTA, White, 10 × 0.5 g | MP-A040500000400 |
| Bone graft | AlloOss. Natural Blend Cortico/Cancellous Particulate, 500–1000 mic. | SKU: 01-108-201 |
Baseline characteristics of study subjects across the 4 study groups.
| Characteristics | Study Groups | |||
|---|---|---|---|---|
| GP | MTA | GP + Bone Graft | MTA + Bone Graft | |
|
| ||||
| Male | 18 (60) | 9 (30) | 8 (26.7) | 18 (60) |
| Female | 40 (40) | 21 (70) | 22 (73.3) | 12 (40) |
|
| ||||
| Canine | 6 (20) | 5 (16.7) | 9 (30) | 5 (16.7) |
| Central incisor | 7 (23.3) | 5 (16.7) | 1 (3.3) | 6 (20) |
| Lateral incisor | 16 (53.4) | 18 (60) | 16 (53.4) | 17 (56.6) |
| Premolar | 1 (3.3) | 2 (6.6) | 4 (13.3) | 2 (6.7) |
|
| ||||
| 11 | 3 (10) | 5 (16.7) | 0 | 2 (6.7) |
| 12 | 5 (16.7) | 9 (30) | 6 (20) | 5 (16.7) |
| 13 | 3 (10) | 3 (10) | 4 (13.3) | 2 (6.7) |
| 21 | 4 (13.3) | 0 | 0 | 4 (13.3) |
| 22 | 11 (36.7) | 9 (30) | 12 (40) | 13 (43.3) |
| 23 | 3 (10) | 2 (6.7) | 5 (16.7) | 3 (10) |
| 24 | 193.3 | 2 (6.7) | 3 (10) | 1 (3.3) |
|
| ||||
| Thick | 1 (3.3) | 3 (10) | 1 (3.3) | 0 |
| Flat and thick | 18 (60) | 13 (43.3) | 17 (56.7) | 18 (60) |
| Scalloped and thin | 11 (36.7) | 14 (46.7) | 12 (40) | 12 (40) |
|
| ||||
| 13.85 (1.48) | 13.20 (1.79) | 13.77 (1.72) | 13.40 (1.69) | |
|
| ||||
| 4.93 (0.91) | 5.03 (0.72) | 4.90 (0.84) | 4.97 (0.72) | |
|
| ||||
| 3.97 (0.93) | 4.03 (0.72) | 3.97 (0.81) | 3.97 (0.67) | |
|
| ||||
| 2.63 (1.13) | 2.10 (0.84) | 2.70 (1.18) | 2.70 (1.21) | |
Comparison of distribution of CBCTPAI among the 4 study groups at each of the 4 time points of follow up visits.
| Outcome Variable & Time Point | Study Groups | ||||
|---|---|---|---|---|---|
| GPA | MTA | GPA + Bone Graft | MTA + Bone Graft | ||
|
| |||||
| 5 + D | 30 (100) | 30 (100) | 30 (100) | 30 (100) | |
|
| |||||
| 2 + D | 0 | 0 | 4 (13.3) | 7 (23.3) | <0.0001 * |
| 3 + D | 13 (43.3) | 30 (100) | 26 (86.7) | 22 (73.3) | |
| 4 | 0 | 0 | 0 | 1 (3.3) | |
| 4 + D | 15 (50) | 0 | 0 | 0 | |
| 5 + D | 2 (6.7) | 0 | 0 | 0 | |
|
| |||||
| 0 | 0 | 0 | 13 (43.3) | 23 (76.7) | <0.0001 * |
| 1 | 0 | 0 | 11 (36.7) | 7 (23.3) | |
| 1 + D | 0 | 28 (93.3) | 0 | 0 | |
| 2 | 0 | 0 | 6 (20) | 0 | |
| 2 + D | 1 (3.3) | 2 (6.7) | 0 | 0 | |
| 3 + D | 29 (96.7) | 0 | 0 | 0 | |
|
| |||||
| 0 | 0 | 0 | 14 (50) | 27 (90) | <0.0001 * |
| 1 | 0 | 0 | 13 (46.4) | 3 (10) | |
| 1 + D | 26 (86.7) | 30 (100) | 0 | 0 | |
| 2 | 0 | 0 | 1(3.6) | 0 | |
| 2 + D | 4 (13.3) | 0 | 0 | 0 | |
* p value.
Figure 1Display of changes in CBCTPAI among the four study groups at each of the four time points of follow up visits.
Comparison of mean PD values among the 4 study groups at each of the 4 time points of follow up visits.
| Time Point | Study Groups | F-Value | ||||
|---|---|---|---|---|---|---|
| GP | MTA | GP + Bone Graft | MTA + Bone Graft | |||
| At 3 months | 3.0 (0.00) | 3.0 (0.00) | 3.10 (0.30) | 3.0 (0.00) | 3.22 | 0.025 |
| At 6 months | 4.37 (0.76) | 3.83 (0.75) | 3.27 (0.45) | 3.00 (0.00) | 33.08 | <0.0001 * |
| At 1 year | 4.80 (0.89) | 3.83 (0.75) | 3.30 (0.59) | 3.00 (0.00) | 44.11 | <0.0001 * |
* p value.